Shafaat A. Rabbani

8.6k total citations · 1 hit paper
136 papers, 6.7k citations indexed

About

Shafaat A. Rabbani is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Shafaat A. Rabbani has authored 136 papers receiving a total of 6.7k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Molecular Biology, 64 papers in Oncology and 47 papers in Cancer Research. Recurrent topics in Shafaat A. Rabbani's work include Protease and Inhibitor Mechanisms (40 papers), Bone health and treatments (37 papers) and Epigenetics and DNA Methylation (31 papers). Shafaat A. Rabbani is often cited by papers focused on Protease and Inhibitor Mechanisms (40 papers), Bone health and treatments (37 papers) and Epigenetics and DNA Methylation (31 papers). Shafaat A. Rabbani collaborates with scholars based in Canada, United States and Israel. Shafaat A. Rabbani's co-authors include David Goltzman, Moshe Szyf, Andrew P. Mazar, Pouya Pakneshan, Niaz Mahmood, Rosie Xing, Ani Arakelian, Gaoping Chen, Catalin Mihalcioiu and Julienne Gladu and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Journal of Clinical Oncology.

In The Last Decade

Shafaat A. Rabbani

135 papers receiving 6.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications

2018 342 citations Niaz Mahmood, Shafaat A. Rabbani et al. Frontiers in Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shafaat A. Rabbani Canada	50	3.9k	2.5k	2.2k	1.1k	684	136	6.7k
M. OʼReilly United States	14	3.7k 0.9×	1.9k 0.8×	2.2k 1.0×	741 0.6×	347 0.5×	30	6.0k
Taina Turpeenniemi‐Hujanen Finland	46	2.1k 0.5×	2.8k 1.2×	3.0k 1.4×	642 0.6×	494 0.7×	150	6.1k
Jasti S. Rao United States	54	4.4k 1.1×	2.4k 0.9×	3.8k 1.8×	500 0.4×	750 1.1×	169	8.3k
Süleyman Ergün Germany	46	4.1k 1.0×	2.0k 0.8×	1.2k 0.6×	937 0.8×	527 0.8×	222	8.3k
Adrian Merlo Switzerland	46	5.8k 1.5×	2.8k 1.1×	1.9k 0.9×	1.1k 1.0×	280 0.4×	89	9.4k
Giuseppe Viglietto Italy	48	5.4k 1.4×	2.3k 0.9×	1.6k 0.7×	803 0.7×	313 0.5×	150	8.2k
Pnina Brodt Canada	46	3.2k 0.8×	2.5k 1.0×	2.2k 1.0×	689 0.6×	239 0.3×	115	6.8k
Giulia Taraboletti Italy	47	4.0k 1.0×	2.1k 0.8×	2.2k 1.0×	506 0.4×	514 0.8×	112	7.1k
Jack Henkin United States	42	2.5k 0.6×	1.3k 0.5×	2.1k 1.0×	532 0.5×	881 1.3×	111	4.8k
Gabri van der Pluijm Netherlands	48	3.5k 0.9×	3.5k 1.4×	1.3k 0.6×	1.3k 1.1×	214 0.3×	129	7.0k

Countries citing papers authored by Shafaat A. Rabbani

Since Specialization

Citations

This map shows the geographic impact of Shafaat A. Rabbani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shafaat A. Rabbani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shafaat A. Rabbani more than expected).

Fields of papers citing papers by Shafaat A. Rabbani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shafaat A. Rabbani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shafaat A. Rabbani. The network helps show where Shafaat A. Rabbani may publish in the future.

Co-authorship network of co-authors of Shafaat A. Rabbani

This figure shows the co-authorship network connecting the top 25 collaborators of Shafaat A. Rabbani. A scholar is included among the top collaborators of Shafaat A. Rabbani based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shafaat A. Rabbani. Shafaat A. Rabbani is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Mahmood, Niaz, et al.. (2025). The Urokinase-Type Plasminogen Activator Receptor (uPAR) as a Mediator of Physiological and Pathological Processes: Potential Therapeutic Strategies. Cancers. 17(20). 3309–3309. 1 indexed citations

Mahmood, Niaz & Shafaat A. Rabbani. (2019). DNA Methylation Readers and Cancer: Mechanistic and Therapeutic Applications. Frontiers in Oncology. 9. 489–489. 87 indexed citations

Stefañska, Barbara, David Cheishvili, Matthew Suderman, et al.. (2014). Genome-Wide Study of Hypomethylated and Induced Genes in Patients with Liver Cancer Unravels Novel Anticancer Targets. Clinical Cancer Research. 20(12). 3118–3132. 91 indexed citations

Harfouche, Rania, et al.. (2010). Estradiol-dependent regulation of angiopoietin expression in breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology. 123(1-2). 17–24. 11 indexed citations

Rabbani, Shafaat A., et al.. (2009). Abstract #2325: Inhibitor of Src kinase SKI-606 (Bosutinb) blocks prostate cancer growth, invasion and experimental skeletal metastases in vitro and in vivo by regulating the expression of key intracellular signaling molecules and genes involved in prostate cancer progression. Cancer Research. 69. 2325–2325. 1 indexed citations

Casimiro, Mathew C., Olga Rodriguez, Llana Pootrakul, et al.. (2007). ErbB-2 Induces the Cyclin D1 Gene in Prostate Epithelial Cells In vitro and In vivo. Cancer Research. 67(9). 4364–4372. 26 indexed citations

Plunkett, M L, et al.. (2004). Regression of primary breast tumor and blockage of osteolytic skeletal metastasis by a non-RGD based integrin binding peptide (ATN-161) targeting α5β1 and αvβ3 in a xenograft model of breast cancer. Cancer Research. 64. 924–924. 1 indexed citations

Gladu, Julienne, et al.. (2003). Androgen Regulation of Parathyroid Hormone-Related Peptide Production in Human Prostate Cancer Cells. Endocrinology. 144(3). 858–867. 16 indexed citations

Rabbani, Shafaat A., et al.. (1998). Effect of nucleoside analogue BCH-4556 on prostate cancer growth and metastases in vitro and in vivo.. PubMed. 58(15). 3461–5. 35 indexed citations

10.

Li, Ming, Rosie Xing, James N. Fryer, et al.. (1997). Expression of Urokinase-Type Plasminogen Activator and Its Receptor during Ovarian Follicular Development¹. Endocrinology. 138(7). 2790–2799. 23 indexed citations

11.

Rabbani, Shafaat A., Penelope Harakidas, Julienne Gladu, et al.. (1997). Expression and characterization of recombinant rat parathyroid hormone-related peptide (1–141) and an amino-terminally-truncated analogue (38–141). Molecular and Cellular Endocrinology. 130(1-2). 13–21. 2 indexed citations

12.

Rabbani, Shafaat A., et al.. (1995). Induction of urinary plasminogen activator by retinoic acid results in increased invasiveness of human prostate cancer cells PC‐3. The Prostate. 27(5). 269–276. 21 indexed citations

13.

Nip, John, Shafaat A. Rabbani, Henry R. Shibata, & Pnina Brodt. (1995). Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells.. Journal of Clinical Investigation. 95(5). 2096–2103. 71 indexed citations

14.

Goltzman, David, et al.. (1995). Processing of pro-PTHRP by the prohormone convertase, furin: effect on biological activity. American Journal of Physiology-Endocrinology and Metabolism. 268(5). E832–E838. 19 indexed citations

15.

Haq, Mahmudul, Richard Kremer, David Goltzman, & Shafaat A. Rabbani. (1993). A vitamin D analogue (EB1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo.. Journal of Clinical Investigation. 91(6). 2416–2422. 66 indexed citations

16.

Rabbani, Shafaat A., Mahmudul Haq, & David Goltzman. (1993). Biosynthesis and processing of endogenous parathyroid hormone related peptide (PTHRP) by rat Leydig cell tumor H-500. Biochemistry. 32(18). 4931–4937. 17 indexed citations

17.

Rabbani, Shafaat A., Toshiyuki Yasuda, H.P.J. Bennett, Geoffrey N. Hendy, & Debra L. Banville. (1992). Nucleotide and (derived) amino acid sequence of a novel peptide from a rat (hypercalcemic) Leydig cell tumor. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression. 1171(2). 229–230. 2 indexed citations

18.

Rabbani, Shafaat A., Wan Keung Wong, K. Anne Kronis, et al.. (1991). Expression and characterization of recombinant human parathyroid hormone-like peptide using a bacterial excretion system. Journal of Bone and Mineral Research. 1 indexed citations

19.

Henderson, Janet E., Chaim Shustik, Richard Kremer, et al.. (1990). Circulating concentrations of parathyroid hormone-like peptide in malignancy and in hyperparathyroidism. Journal of Bone and Mineral Research. 5(2). 105–113. 115 indexed citations

20.

Rabbani, Shafaat A., J. Mitchell, Denis Roy, Geoffrey N. Hendy, & David Goltzman. (1988). Influence of the Amino-Terminus onin Vitroandin VivoBiological Activity of Synthetic Parathyroid Hormone-Like Peptides of Malignancy*. Endocrinology. 123(6). 2709–2716. 66 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact